Meeting
2024 ASCO Breakthrough
CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor.
Authors
Hidekazu Hirano
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
Hidekazu Hirano , Yoichi Naito , Raghav Sundar , Yoshito Komatsu , Yukinori Kurokawa , Jian Li , Masato Ozaka , Masaaki Iwatsuki , Jen-Shi Chen , Chueh-Chuan Yen , John Raymond Zalcberg , Amitesh Chandra Roy , Li-Tzong Chen , Toshirou Nishida , Toshihiko Doi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Advanced Disease
Clinical Trial Registration Number
NCT05245968
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr TPS97)
DOI
10.1200/JCO.2024.42.23_suppl.TPS97
Abstract #
TPS97
Poster Bd #
L6
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
First Author: Yoshitaka Honma
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
First Author: Michael C. Heinrich
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).
First Author: Suzanne George
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick